PolandPoland

Early GM use holds large benefits

10.07.2005

Canterbury - Early adoption of GM technology in arable crops would bring clear farm level and environmental benefits for Poland according to a new report by Graham Brookes, of Brooks West, UK, and Prof. Andrzej Aniol, from the Polish Plant Breeding and Acclimatization Institute, published in the journal Biotechnologica.
The report shows that the application and use of the GM agronomic traits of herbicide tolerance to oilseed rape, sugar beet and maize, and insect (Bt) resistance in maize offers Poland both economic and environmental benefits.
The authors claim that Polish arable farmers have the potential to gain more from early adoption of GM technology than their EU 15 counterparts because they are starting from a lower average level of technical efficiency that enables Polish producers to compete more effectively, and earlier than they might otherwise have been capable of, if they did not use GM technology. Key findings forecast that adoption of GM technology would result in annual increases in output of between 10% and 19% for crops like oilseed rape (for export and as a raw material for bio-fuels) and sugar beet (for export without EU subsidy or for use in non-food sectors like bio-ethanol).
This represents an increase in farm (gross margin) income of between Euro67 million and Euro123 million. There will be greater opportunities to move to low tillage cultivation methods, which reduce soil disruption, erosion, and the release of carbon dioxide from ploughing and hence make a positive contribution to reducing the impact of global warming.

PolandPoland

07.03.2012

Polish antibody development and manufacturing specialist Mabion S.A. more than tripled its revenues in 2011 (€2.5m) compared to 2010 (€0.74m). The increase in turnover mainly resulted from stronger client demand for R&D services...

PolandPoland

01.03.2012

Polish company Bioton S.A (Warsaw) and Swiss-headquartered generics giant Actavis (Zug) have joined forces to shake up the €12bn world market for recombinant insulins and insulin analogues. At the end of January, Bioton Chairman...

PolandPoland

31.01.2012

Zug/Warsaw - The fourth largest generics producer and a polish biotech want to create a stir in the market for diabetes drugs. Swiss Actavis and Bioton from Warsaw announced that they have formed a joint venture company for the...

PolandPoland

10.12.2011

Krakow – Polish Selvita S.A., which offers preclinical drug development services to pharma companies, has been ranked as the No. 1 “Rising Star” of this year’s Fast50 contest. In the programme, analysts from Deloitte Technology...

PolandPoland

09.12.2011

Warsaw – Poland’s Bioton S.A. has announced it is investing €20m in a new production plant in Szczecin. The biotechnology company is planning to manufacture insulin injection devices in the facility. The project involves the...

PolandPoland

01.10.2011

Warsaw – Biotech experts want to make the development of pharmaceutical and medical innovations a priority in Poland. At the start of September, members of the Polish Technology Platform for Innovative Medicine recommended that...

PolandPoland

02.08.2011

Kraków – Selvita SA CEO Pawel Przewiezlikowski announced at the end of July that the Polish drug development and drug discovery service firm is close to achieving profitability. After bagging EUR3.7m through an IPO on Warsaw’s...

PolandPoland

12.06.2011

Warsaw – Researchers from Lodz and Poznan Universities say Poland needs to update its draft GMO law. “The national current legal situation is complicated,” Prof. Tomas Twardowski told EuroBiotechNews, stressing that while trade...

PolandPoland

12.06.2011

Krakow – Polish Selvita S.A. is going public. By May, the drug discovery specialist announced it had entered into definite agreements with investors to sell 2.7 million shares for a total of EUR3.75m, resulting in a market...

PolandPoland

11.06.2011

Szczecin/Greifswald – A team of physical chemists headed by Robert Hoylst from the Polish Academy of Science have improved a method for calculating the migration time of drugs or drug delivery devices introduced into the sol/gel...

Displaying results 1 to 10 out of 108

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-poland/article/early-gm-use-holds-large-benefits.html

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.22 EUR0.00%
  • ACTELION111.20 CHF0.00%
  • ADDEX3.98 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.22 EUR0.00%
  • ACTELION111.20 CHF0.00%

TOP

  • SANTHERA98.35 CHF64.2%
  • EPIGENOMICS3.37 EUR6.0%
  • BB BIOTECH141.00 EUR5.9%

FLOP

  • WILEX2.25 EUR-20.2%
  • MOLOGEN7.38 EUR-16.3%
  • THERAMETRICS0.08 CHF-11.1%

TOP

  • SANTHERA98.35 CHF4310.3%
  • CO.DON2.48 EUR210.0%
  • PAION2.43 EUR173.0%

FLOP

  • CYTOS0.25 CHF-93.7%
  • MEDIGENE4.55 EUR-67.3%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 29.08.2014


Current issue

All issues

Product of the week

Products